Cardiology has been a quiet area for new drug approvals over the past decade, but the field is heading into what could be a productive period. Candidates are under review both for heart failure patients with reduced ejection fraction and those with preserved ejection fraction, while a race is developing in obstructive hypertrophic cardiomyopathy treatment between two candidates with a common forebearer.
Notably, two of the pending applications hold a breakthrough therapy designation (BTD): Bristol Myers Squibb Company’s mavacamten for obstructive...








